Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 175

1.

A comprehensive, multidisciplinary, precision medicine approach to discover effective therapy for an undiagnosed, progressive, fibroinflammatory disease.

Gochuico BR, Ziegler SG, Ten NS, Balanda NJ, Mason CE, Zumbo P, Evans CA, Van Waes C, Gahl WA, Malicdan MCV.

Transl Res. 2019 Aug 28. pii: S1931-5244(19)30171-9. doi: 10.1016/j.trsl.2019.08.008. [Epub ahead of print]

PMID:
31520587
2.

Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer.

Park SJ, Ye W, Xiao R, Silvin C, Padget M, Hodge JW, Van Waes C, Schmitt NC.

Oral Oncol. 2019 Aug;95:127-135. doi: 10.1016/j.oraloncology.2019.06.016. Epub 2019 Jun 20.

PMID:
31345380
3.

Dual Antagonist of cIAP/XIAP ASTX660 Sensitizes HPV(-) and HPV(+) Head and Neck Cancers To TNFα, TRAIL, and Radiation Therapy.

Xiao R, An Y, Ye W, Derakhshan A, Cheng H, Yang X, Allen C, Chen Z, Schmitt NC, Van Waes C.

Clin Cancer Res. 2019 Jul 2. pii: clincanres.3802.2018. doi: 10.1158/1078-0432.CCR-18-3802. [Epub ahead of print]

PMID:
31266830
4.

Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.

Sun L, Clavijo PE, Robbins Y, Patel P, Friedman J, Greene S, Das R, Silvin C, Van Waes C, Horn LA, Schlom J, Palena C, Maeda D, Zebala J, Allen CT.

JCI Insight. 2019 Apr 4;4(7). pii: 126853. doi: 10.1172/jci.insight.126853. eCollection 2019 Apr 4.

5.

Integrated Genomic and Functional microRNA Analysis Identifies miR-30-5p as a Tumor Suppressor and Potential Therapeutic Nanomedicine in Head and Neck Cancer.

Saleh AD, Cheng H, Martin SE, Si H, Ormanoglu P, Carlson S, Clavijo PE, Yang X, Das R, Cornelius S, Couper J, Chepeha D, Danilova L, Harris TM, Prystowsky MB, Childs GJ, Smith RV, Robertson AG, Jones SJM, Cherniack AD, Kim SS, Rait A, Pirollo KF, Chang EH, Chen Z, Van Waes C.

Clin Cancer Res. 2019 May 1;25(9):2860-2873. doi: 10.1158/1078-0432.CCR-18-0716. Epub 2019 Feb 5.

PMID:
30723145
6.

Lymphotoxin-β receptor-NIK signaling induces alternative RELB/NF-κB2 activation to promote metastatic gene expression and cell migration in head and neck cancer.

Das R, Coupar J, Clavijo PE, Saleh A, Cheng TF, Yang X, Chen J, Van Waes C, Chen Z.

Mol Carcinog. 2019 Mar;58(3):411-425. doi: 10.1002/mc.22938. Epub 2018 Nov 28.

PMID:
30488488
7.

Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial.

Day TA, Shirai K, O'Brien PE, Matheus MG, Godwin K, Sood AJ, Kompelli A, Vick JA, Martin D, Vitale-Cross L, Callejas-Varela JL, Wang Z, Wu X, Harismendy O, Molinolo AA, Lippman SM, Van Waes C, Szabo E, Gutkind JS.

Clin Cancer Res. 2019 Feb 15;25(4):1156-1164. doi: 10.1158/1078-0432.CCR-18-2024. Epub 2018 Nov 12.

PMID:
30420444
8.

Antagonist of cIAP1/2 and XIAP enhances anti-tumor immunity when combined with radiation and PD-1 blockade in a syngeneic model of head and neck cancer.

Xiao R, Allen CT, Tran L, Patel P, Park SJ, Chen Z, Van Waes C, Schmitt NC.

Oncoimmunology. 2018 Aug 1;7(9):e1471440. doi: 10.1080/2162402X.2018.1471440. eCollection 2018.

9.

Genomic and Transcriptomic Characterization Links Cell Lines with Aggressive Head and Neck Cancers.

Cheng H, Yang X, Si H, Saleh AD, Xiao W, Coupar J, Gollin SM, Ferris RL, Issaeva N, Yarbrough WG, Prince ME, Carey TE, Van Waes C, Chen Z.

Cell Rep. 2018 Oct 30;25(5):1332-1345.e5. doi: 10.1016/j.celrep.2018.10.007.

10.

WEE1 kinase inhibition reverses G2/M cell cycle checkpoint activation to sensitize cancer cells to immunotherapy.

Sun L, Moore E, Berman R, Clavijo PE, Saleh A, Chen Z, Van Waes C, Davies J, Friedman J, Allen CT.

Oncoimmunology. 2018 Jul 23;7(10):e1488359. doi: 10.1080/2162402X.2018.1488359. eCollection 2018.

11.

Corrigendum to "The role of protein methyltransferases as potential novel therapeutic targets in squamous cell carcinoma of the head and neck" [Oral Oncol. 81 (2018) 100-108].

Saloura V, Vougiouklakis T, Burkitt K, Nakamura Y, Hager GL, van Waes C.

Oral Oncol. 2018 Nov;86:318. doi: 10.1016/j.oraloncology.2018.08.022. Epub 2018 Sep 7. No abstract available.

12.

Targeting Notch1 and IKKα Enhanced NF-κB Activation in CD133+ Skin Cancer Stem Cells.

Quan XX, Hawk NV, Chen W, Coupar J, Lee SK, Petersen DW, Meltzer PS, Montemarano A, Braun M, Chen Z, Van Waes C.

Mol Cancer Ther. 2018 Sep;17(9):2034-2048. doi: 10.1158/1535-7163.MCT-17-0421. Epub 2018 Jun 29.

13.

Attenuated TRAF3 Fosters Activation of Alternative NF-κB and Reduced Expression of Antiviral Interferon, TP53, and RB to Promote HPV-Positive Head and Neck Cancers.

Zhang J, Chen T, Yang X, Cheng H, Späth SS, Clavijo PE, Chen J, Silvin C, Issaeva N, Su X, Yarbrough WG, Annunziata CM, Chen Z, Van Waes C.

Cancer Res. 2018 Aug 15;78(16):4613-4626. doi: 10.1158/0008-5472.CAN-17-0642. Epub 2018 Jun 19.

14.

Nanocomplex-based TP53 gene therapy promotes anti-tumor immunity through TP53- and STING-dependent mechanisms.

Moore EC, Sun L, Clavijo PE, Friedman J, Harford JB, Saleh AD, Van Waes C, Chang EH, Allen CT.

Oncoimmunology. 2018 May 7;7(7):e1404216. doi: 10.1080/2162402X.2017.1404216. eCollection 2018. Erratum in: Oncoimmunology. 2018 Dec 13;8(2):e1534569.

15.

The role of protein methyltransferases as potential novel therapeutic targets in squamous cell carcinoma of the head and neck.

Saloura V, Vougiouklakis T, Sievers C, Burkitt K, Nakamura Y, Hager G, van Waes C.

Oral Oncol. 2018 Jun;81:100-108. doi: 10.1016/j.oraloncology.2018.04.014. Epub 2018 May 3. Review. Erratum in: Oral Oncol. 2018 Nov;86:318.

16.

Monitoring the Impact of Hedgerows and Grass Strips on the Performance of Multiple Ecosystem Service Indicators.

Van Vooren L, Reubens B, Ampoorter E, Broekx S, Pardon P, Van Waes C, Verheyen K.

Environ Manage. 2018 Aug;62(2):241-259. doi: 10.1007/s00267-018-1043-4. Epub 2018 May 31.

PMID:
29855687
17.

Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas.

Campbell JD, Yau C, Bowlby R, Liu Y, Brennan K, Fan H, Taylor AM, Wang C, Walter V, Akbani R, Byers LA, Creighton CJ, Coarfa C, Shih J, Cherniack AD, Gevaert O, Prunello M, Shen H, Anur P, Chen J, Cheng H, Hayes DN, Bullman S, Pedamallu CS, Ojesina AI, Sadeghi S, Mungall KL, Robertson AG, Benz C, Schultz A, Kanchi RS, Gay CM, Hegde A, Diao L, Wang J, Ma W, Sumazin P, Chiu HS, Chen TW, Gunaratne P, Donehower L, Rader JS, Zuna R, Al-Ahmadie H, Lazar AJ, Flores ER, Tsai KY, Zhou JH, Rustgi AK, Drill E, Shen R, Wong CK; Cancer Genome Atlas Research Network, Stuart JM, Laird PW, Hoadley KA, Weinstein JN, Peto M, Pickering CR, Chen Z, Van Waes C.

Cell Rep. 2018 Apr 3;23(1):194-212.e6. doi: 10.1016/j.celrep.2018.03.063.

18.

PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation.

Morisada M, Clavijo PE, Moore E, Sun L, Chamberlin M, Van Waes C, Hodge JW, Mitchell JB, Friedman J, Allen CT.

Oncoimmunology. 2017 Nov 27;7(3):e1395996. doi: 10.1080/2162402X.2017.1395996. eCollection 2018.

19.

Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma.

Tran L, Allen CT, Xiao R, Moore E, Davis R, Park SJ, Spielbauer K, Van Waes C, Schmitt NC.

Cancer Immunol Res. 2017 Dec;5(12):1141-1151. doi: 10.1158/2326-6066.CIR-17-0235. Epub 2017 Nov 2.

20.

Genomics and advances towards precision medicine for head and neck squamous cell carcinoma.

Van Waes C, Musbahi O.

Laryngoscope Investig Otolaryngol. 2017 Aug 22;2(5):310-319. doi: 10.1002/lio2.86. eCollection 2017 Oct. Review.

21.

Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells.

Clavijo PE, Moore EC, Chen J, Davis RJ, Friedman J, Kim Y, Van Waes C, Chen Z, Allen CT.

Oncotarget. 2017 Jun 11;8(34):55804-55820. doi: 10.18632/oncotarget.18437. eCollection 2017 Aug 22.

22.

Nine patients with chronic granulomatous disease having selective neck dissection for severe cervical lymphadenitis.

Wingfield LR, Liu J, Hu M, Bianchi D, Hauck K, Driscoll B, Gallin JI, Malech HL, Holland SM, Van Waes C.

Clin Otolaryngol. 2018 Feb;43(1):335-340. doi: 10.1111/coa.12943. Epub 2017 Aug 17. No abstract available.

23.

A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations.

Zhang Y, Kwok-Shing Ng P, Kucherlapati M, Chen F, Liu Y, Tsang YH, de Velasco G, Jeong KJ, Akbani R, Hadjipanayis A, Pantazi A, Bristow CA, Lee E, Mahadeshwar HS, Tang J, Zhang J, Yang L, Seth S, Lee S, Ren X, Song X, Sun H, Seidman J, Luquette LJ, Xi R, Chin L, Protopopov A, Westbrook TF, Shelley CS, Choueiri TK, Ittmann M, Van Waes C, Weinstein JN, Liang H, Henske EP, Godwin AK, Park PJ, Kucherlapati R, Scott KL, Mills GB, Kwiatkowski DJ, Creighton CJ.

Cancer Cell. 2017 Jun 12;31(6):820-832.e3. doi: 10.1016/j.ccell.2017.04.013. Epub 2017 May 18.

24.

Potential of chopped heath biomass and spent growth media to replace wood chips as bulking agent for composting high N-containing residues.

Viaene J, Reubens B, Willekens K, Van Waes C, De Neve S, Vandecasteele B.

J Environ Manage. 2017 Jul 15;197:338-350. doi: 10.1016/j.jenvman.2017.03.086. Epub 2017 Apr 9.

PMID:
28402916
25.

Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3Kδ/γ.

Davis RJ, Moore EC, Clavijo PE, Friedman J, Cash H, Chen Z, Silvin C, Van Waes C, Allen C.

Cancer Res. 2017 May 15;77(10):2607-2619. doi: 10.1158/0008-5472.CAN-16-2534. Epub 2017 Mar 31.

26.

Genetic alterations in TRAF3 and CYLD that regulate nuclear factor κB and interferon signaling define head and neck cancer subsets harboring human papillomavirus.

Chen T, Zhang J, Chen Z, Van Waes C.

Cancer. 2017 May 15;123(10):1695-1698. doi: 10.1002/cncr.30659. Epub 2017 Mar 13. No abstract available.

27.

Therapeutic Small Molecules Target Inhibitor of Apoptosis Proteins in Cancers with Deregulation of Extrinsic and Intrinsic Cell Death Pathways.

Derakhshan A, Chen Z, Van Waes C.

Clin Cancer Res. 2017 Mar 15;23(6):1379-1387. doi: 10.1158/1078-0432.CCR-16-2172. Epub 2016 Dec 30. Review.

28.

Established T Cell-Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade.

Moore E, Clavijo PE, Davis R, Cash H, Van Waes C, Kim Y, Allen C.

Cancer Immunol Res. 2016 Dec;4(12):1061-1071. Epub 2016 Nov 7.

29.

TNF-α modulates genome-wide redistribution of ΔNp63α/TAp73 and NF-κB cREL interactive binding on TP53 and AP-1 motifs to promote an oncogenic gene program in squamous cancer.

Si H, Lu H, Yang X, Mattox A, Jang M, Bian Y, Sano E, Viadiu H, Yan B, Yau C, Ng S, Lee SK, Romano RA, Davis S, Walker RL, Xiao W, Sun H, Wei L, Sinha S, Benz CC, Stuart JM, Meltzer PS, Van Waes C, Chen Z.

Oncogene. 2016 Nov 3;35(44):5781-5794. doi: 10.1038/onc.2016.112. Epub 2016 May 2.

30.

Putting T cells to work-outsourcing neoantigen detection in head and neck cancers?

Xiao R, Van Waes C, Schmitt NC.

Oral Dis. 2017 Oct;23(7):820-821. doi: 10.1111/odi.12604. Epub 2016 Nov 28. No abstract available.

31.

SMAC Mimetic Birinapant plus Radiation Eradicates Human Head and Neck Cancers with Genomic Amplifications of Cell Death Genes FADD and BIRC2.

Eytan DF, Snow GE, Carlson S, Derakhshan A, Saleh A, Schiltz S, Cheng H, Mohan S, Cornelius S, Coupar J, Sowers AL, Hernandez L, Mitchell JB, Annunziata CM, Chen Z, Van Waes C.

Cancer Res. 2016 Sep 15;76(18):5442-5454. doi: 10.1158/0008-5472.CAN-15-3317. Epub 2016 Jul 28.

32.

Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer.

Davis RJ, Van Waes C, Allen CT.

Oral Oncol. 2016 Jul;58:59-70. doi: 10.1016/j.oraloncology.2016.05.002. Epub 2016 May 20. Review.

33.

Bipedicled DIEAP flaps for reconstruction of limb soft tissue defects in male patients.

Mahajan AL, Van Waes C, D'Arpa S, Van Landuyt K, Blondeel PN, Monstrey S, Stillaert FB.

J Plast Reconstr Aesthet Surg. 2016 Jul;69(7):920-7. doi: 10.1016/j.bjps.2016.03.015. Epub 2016 Apr 12.

PMID:
27157537
34.

Unilateral Cervical Polyneuropathies following Concurrent Bortezomib, Cetuximab, and Radiotherapy for Head and Neck Cancer.

Elghouche A, Shokri T, Qin Y, Wargo S, Citrin D, Van Waes C.

Case Rep Otolaryngol. 2016;2016:2313714. doi: 10.1155/2016/2313714. Epub 2016 Feb 25.

35.

Enhanced Tumor Control with Combination mTOR and PD-L1 Inhibition in Syngeneic Oral Cavity Cancers.

Moore EC, Cash HA, Caruso AM, Uppaluri R, Hodge JW, Van Waes C, Allen CT.

Cancer Immunol Res. 2016 Jul;4(7):611-20. doi: 10.1158/2326-6066.CIR-15-0252. Epub 2016 Apr 13.

36.

DIEAP flap for safe definitive autologous breast reconstruction.

Seidenstuecker K, van Waes C, Munder BI, Claes KE, Witzel C, Roche N, Stillaert F, Mahajan AL, Andree C, Blondeel PN.

Breast. 2016 Apr;26:59-66. doi: 10.1016/j.breast.2015.12.005. Epub 2016 Jan 27.

PMID:
27017243
37.

Clonally expanded CD4+ T cells can produce infectious HIV-1 in vivo.

Simonetti FR, Sobolewski MD, Fyne E, Shao W, Spindler J, Hattori J, Anderson EM, Watters SA, Hill S, Wu X, Wells D, Su L, Luke BT, Halvas EK, Besson G, Penrose KJ, Yang Z, Kwan RW, Van Waes C, Uldrick T, Citrin DE, Kovacs J, Polis MA, Rehm CA, Gorelick R, Piatak M, Keele BF, Kearney MF, Coffin JM, Hughes SH, Mellors JW, Maldarelli F.

Proc Natl Acad Sci U S A. 2016 Feb 16;113(7):1883-8. doi: 10.1073/pnas.1522675113. Epub 2016 Feb 8.

38.

Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches.

Allen CT, Clavijo PE, Van Waes C, Chen Z.

Cancers (Basel). 2015 Dec 9;7(4):2397-414. doi: 10.3390/cancers7040900. Review.

39.

mTOR and MEK1/2 inhibition differentially modulate tumor growth and the immune microenvironment in syngeneic models of oral cavity cancer.

Cash H, Shah S, Moore E, Caruso A, Uppaluri R, Van Waes C, Allen C.

Oncotarget. 2015 Nov 3;6(34):36400-17. doi: 10.18632/oncotarget.5063.

40.

Integrated transcriptional profiling and genomic analyses reveal RPN2 and HMGB1 as promising biomarkers in colorectal cancer.

Zhang J, Yan B, Späth SS, Qun H, Cornelius S, Guan D, Shao J, Hagiwara K, Van Waes C, Chen Z, Su X, Bi Y.

Cell Biosci. 2015 Sep 17;5:53. doi: 10.1186/s13578-015-0043-9. eCollection 2015.

41.

Conditional deletion of nonmuscle myosin II-A in mouse tongue epithelium results in squamous cell carcinoma.

Conti MA, Saleh AD, Brinster LR, Cheng H, Chen Z, Cornelius S, Liu C, Ma X, Van Waes C, Adelstein RS.

Sci Rep. 2015 Sep 15;5:14068. doi: 10.1038/srep14068.

42.

Genetic Landscape of Human Papillomavirus-Associated Head and Neck Cancer and Comparison to Tobacco-Related Tumors.

Hayes DN, Van Waes C, Seiwert TY.

J Clin Oncol. 2015 Oct 10;33(29):3227-34. doi: 10.1200/JCO.2015.62.1086. Epub 2015 Sep 8. Review.

43.

MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.

Mohan S, Vander Broek R, Shah S, Eytan DF, Pierce ML, Carlson SG, Coupar JF, Zhang J, Cheng H, Chen Z, Van Waes C.

Clin Cancer Res. 2015 Sep 1;21(17):3946-56. doi: 10.1158/1078-0432.CCR-14-3377. Epub 2015 May 14.

44.

Immunohistochemical analysis of NF-κB in human tumor tissue.

Allen CT, Van Waes C.

Methods Mol Biol. 2015;1280:459-68. doi: 10.1007/978-1-4939-2422-6_28.

PMID:
25736767
45.

CCR 20th anniversary commentary: Preclinical study of proteasome inhibitor bortezomib in head and neck cancer.

Allen CT, Conley B, Sunwoo JB, Van Waes C.

Clin Cancer Res. 2015 Mar 1;21(5):942-3. doi: 10.1158/1078-0432.CCR-14-2550.

46.

Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384.

Leiker AJ, DeGraff W, Choudhuri R, Sowers AL, Thetford A, Cook JA, Van Waes C, Mitchell JB.

Clin Cancer Res. 2015 Jun 15;21(12):2792-801. doi: 10.1158/1078-0432.CCR-14-3279. Epub 2015 Feb 27.

47.

Combination effects of SMAC mimetic birinapant with TNFα, TRAIL, and docetaxel in preclinical models of HNSCC.

Eytan DF, Snow GE, Carlson SG, Schiltz S, Chen Z, Van Waes C.

Laryngoscope. 2015 Mar;125(3):E118-24. doi: 10.1002/lary.25056. Epub 2014 Nov 28.

48.

CK2 phosphorylates and inhibits TAp73 tumor suppressor function to promote expression of cancer stem cell genes and phenotype in head and neck cancer.

Lu H, Yan C, Quan XX, Yang X, Zhang J, Bian Y, Chen Z, Van Waes C.

Neoplasia. 2014 Oct 23;16(10):789-800. doi: 10.1016/j.neo.2014.08.014. eCollection 2014 Oct.

49.

Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin.

Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, Leiserson MDM, Niu B, McLellan MD, Uzunangelov V, Zhang J, Kandoth C, Akbani R, Shen H, Omberg L, Chu A, Margolin AA, Van't Veer LJ, Lopez-Bigas N, Laird PW, Raphael BJ, Ding L, Robertson AG, Byers LA, Mills GB, Weinstein JN, Van Waes C, Chen Z, Collisson EA; Cancer Genome Atlas Research Network, Benz CC, Perou CM, Stuart JM.

Cell. 2014 Aug 14;158(4):929-944. doi: 10.1016/j.cell.2014.06.049. Epub 2014 Aug 7.

50.

The structural network of Interleukin-10 and its implications in inflammation and cancer.

Acuner-Ozbabacan ES, Engin BH, Guven-Maiorov E, Kuzu G, Muratcioglu S, Baspinar A, Chen Z, Van Waes C, Gursoy A, Keskin O, Nussinov R.

BMC Genomics. 2014;15 Suppl 4:S2. doi: 10.1186/1471-2164-15-S4-S2. Epub 2014 May 20.

Supplemental Content

Loading ...
Support Center